Derek Archila
Stock Analyst at Wells Fargo
(3.66)
# 844
Out of 4,732 analysts
163
Total ratings
43.64%
Success rate
8.61%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $639 → $723 | $640.52 | +12.88% | 10 | Dec 19, 2024 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $12 → $14 | $13.88 | +0.86% | 5 | Dec 19, 2024 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $11 → $9 | $6.19 | +45.40% | 11 | Dec 19, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $68 → $70 | $71.93 | -2.68% | 6 | Dec 19, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $47 → $45 | $23.86 | +88.60% | 9 | Dec 19, 2024 | |
| CABA Cabaletta Bio | Downgrades: Equal-Weight | $12 → $6 | $2.74 | +118.98% | 8 | Dec 19, 2024 | |
| CCCC C4 Therapeutics | Upgrades: Overweight | $8 → $12 | $3.94 | +204.57% | 5 | Dec 19, 2024 | |
| GLUE Monte Rosa Therapeutics | Downgrades: Equal-Weight | $14 → $11 | $5.66 | +94.52% | 4 | Dec 19, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Equal-Weight | $27 | $18.13 | +48.92% | 1 | Dec 19, 2024 | |
| ANAB AnaptysBio | Maintains: Overweight | $56 → $40 | $15.85 | +152.37% | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $1.99 | +553.27% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $95 → $16 | $3.28 | +387.80% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $40.61 | +40.36% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $16.89 | +154.59% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.33 | +620.72% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $29.94 | +0.22% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $110.05 | +37.21% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $36 | $36.20 | -0.55% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.61 | +370.91% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $128.13 | +125.55% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.02 | +444.55% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $23.78 | +55.59% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $29 → $9 | $2.24 | +301.79% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.20 | +138.10% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $60 | $18.05 | +232.41% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $54.54 | -4.66% | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $19.14 | +4.49% | 4 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.21 | +804.98% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.16 | +733.33% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.47 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $23.76 | +712.29% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $108.96 | -62.37% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $0.56 | +1,333.69% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $4.47 | +1,243.78% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.36 | +565.14% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.63 | +2,967.48% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.27 | +396.59% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $23.84 | +269.13% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $22.36 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $21.92 | - | 2 | Aug 3, 2017 |
argenx SE
Dec 19, 2024
Maintains: Overweight
Price Target: $639 → $723
Current: $640.52
Upside: +12.88%
Zymeworks
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $13.88
Upside: +0.86%
Kezar Life Sciences
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.19
Upside: +45.40%
Incyte
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $68 → $70
Current: $71.93
Upside: -2.68%
Immunovant
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $23.86
Upside: +88.60%
Cabaletta Bio
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $12 → $6
Current: $2.74
Upside: +118.98%
C4 Therapeutics
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $3.94
Upside: +204.57%
Monte Rosa Therapeutics
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $14 → $11
Current: $5.66
Upside: +94.52%
Viridian Therapeutics
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $18.13
Upside: +48.92%
AnaptysBio
Dec 12, 2024
Maintains: Overweight
Price Target: $56 → $40
Current: $15.85
Upside: +152.37%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $1.99
Upside: +553.27%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $95 → $16
Current: $3.28
Upside: +387.80%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $40.61
Upside: +40.36%
Nov 19, 2024
Initiates: Overweight
Price Target: $43
Current: $16.89
Upside: +154.59%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.33
Upside: +620.72%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $29.94
Upside: +0.22%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $110.05
Upside: +37.21%
Oct 30, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $36.20
Upside: -0.55%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $3.61
Upside: +370.91%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $128.13
Upside: +125.55%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.02
Upside: +444.55%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $23.78
Upside: +55.59%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29 → $9
Current: $2.24
Upside: +301.79%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $4.20
Upside: +138.10%
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $18.05
Upside: +232.41%
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $54.54
Upside: -4.66%
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $19.14
Upside: +4.49%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.21
Upside: +804.98%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $2.16
Upside: +733.33%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.47
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $23.76
Upside: +712.29%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $108.96
Upside: -62.37%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $0.56
Upside: +1,333.69%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $4.47
Upside: +1,243.78%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.36
Upside: +565.14%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.63
Upside: +2,967.48%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.27
Upside: +396.59%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $23.84
Upside: +269.13%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $22.36
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $21.92
Upside: -